Showing 1,601 - 1,620 results of 103,778 for search '(( e point decrease ) OR ( 5 ((((wt decrease) OR (we decrease))) OR (a decrease)) ))', query time: 1.53s Refine Results
  1. 1601
  2. 1602
  3. 1603

    Impaired Telomere Maintenance and Decreased Canonical WNT Signaling but Normal Ribosome Biogenesis in Induced Pluripotent Stem Cells from X-Linked Dyskeratosis Congenita Patients by Bai-Wei Gu (740949)

    Published 2015
    “…Here we describe the production of iPS cells from DC patients with <i>DKC1 </i>mutations <i>Q31E</i>, <i>A353V </i>and <i>ΔL37</i>. …”
  4. 1604
  5. 1605
  6. 1606

    Inhibition of HDAC6 activity decreased the levels of EGFR and increased acetyl-α-tubulin in renal epithelial cells. by Wei Liu (20030)

    Published 2013
    “…<p>(A) and (B) Western blotting analysis of the expression of EGFR and acetyl-α-tubulin in <i>Pkd1</i> wild-type (WT) MEK cells (A) and <i>Pkd1<sup>null/null</sup></i> (Null) MEK cells (B) treated with or without tubacin. …”
  7. 1607
  8. 1608

    Adenosine decreases the number of releasable vesicles and release probability without changing the rate of recovery from vesicle depletion. by Shouping Wang (402959)

    Published 2013
    “…The amplitude of EPSC evoked by each stimulus was measured by resetting the base line each time at a point within 0.5 ms before the beginning of each stimulation artifact. …”
  9. 1609
  10. 1610
  11. 1611
  12. 1612

    Image_1_TRAPS mutations in Tnfrsf1a decrease the responsiveness to TNFα via reduced cell surface expression of TNFR1.tif by Takahiko Akagi (13138338)

    Published 2022
    “…T79M is a known mutation responsible for TRAPS, whereas G87V is a TRAPS mutation that we have reported, and T90I is a variant of unknown significance. …”
  13. 1613

    Image_4_TRAPS mutations in Tnfrsf1a decrease the responsiveness to TNFα via reduced cell surface expression of TNFR1.tif by Takahiko Akagi (13138338)

    Published 2022
    “…T79M is a known mutation responsible for TRAPS, whereas G87V is a TRAPS mutation that we have reported, and T90I is a variant of unknown significance. …”
  14. 1614

    Image_7_TRAPS mutations in Tnfrsf1a decrease the responsiveness to TNFα via reduced cell surface expression of TNFR1.tif by Takahiko Akagi (13138338)

    Published 2022
    “…T79M is a known mutation responsible for TRAPS, whereas G87V is a TRAPS mutation that we have reported, and T90I is a variant of unknown significance. …”
  15. 1615

    Image_3_TRAPS mutations in Tnfrsf1a decrease the responsiveness to TNFα via reduced cell surface expression of TNFR1.tif by Takahiko Akagi (13138338)

    Published 2022
    “…T79M is a known mutation responsible for TRAPS, whereas G87V is a TRAPS mutation that we have reported, and T90I is a variant of unknown significance. …”
  16. 1616

    Image_6_TRAPS mutations in Tnfrsf1a decrease the responsiveness to TNFα via reduced cell surface expression of TNFR1.tif by Takahiko Akagi (13138338)

    Published 2022
    “…T79M is a known mutation responsible for TRAPS, whereas G87V is a TRAPS mutation that we have reported, and T90I is a variant of unknown significance. …”
  17. 1617

    Image_2_TRAPS mutations in Tnfrsf1a decrease the responsiveness to TNFα via reduced cell surface expression of TNFR1.tif by Takahiko Akagi (13138338)

    Published 2022
    “…T79M is a known mutation responsible for TRAPS, whereas G87V is a TRAPS mutation that we have reported, and T90I is a variant of unknown significance. …”
  18. 1618

    The decrease in lactate induced by pyruvate is blocked by inhibition of MAS and of the TCA cycle in HKI/HKII double KD cells. by Scott John (228011)

    Published 2023
    “…Following the decrease in lactate evoked by pyruvate, addition of AOA reversed this effect, causing a rapid increase in lactate. …”
  19. 1619
  20. 1620

    DataSheet_1_Failure to decrease HbA1c levels following TB treatment is associated with elevated Th1/Th17 CD4+ responses.pdf by Robert Krause (504842)

    Published 2023
    “…Participants were stratified based on stable/increased HbA1c (n = 16) versus decreased HbA1c (n = 46) levels from treatment initiation to 12 month follow-up.…”